Loading
A phase 2 trial of durvalumab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer, run by Fudan University, now recruiting.
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer is a phase 2 interventional study registered as NCT06591650 by Fudan University, with a registry enrolment figure of 33 participants, started 2024-10-24 and due to reach its primary completion in 2026-10-30. Interventions recorded: gemcitabine hydrochloride, Cisplatin, Nab-paclitaxel, Durvalumab. Conditions listed: Gallbladder Cancer Unresectable. Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Gemcitabine and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.